BC-415 1430-Avoiding Financial Toxicity for Study Participants

MAGI 2024: The Clinical Research Conference

Please let us know what you thought of this session.
1.Please give an overall rating for this session.
1 Star = Poor | 4 Stars = Excellent
Poor
Below Average
Above Average
Excellent
2.Did the session meet the specified session description?
3.The speaker was well prepared.
Strongly disagree
Disagree
Agree
Strongly agree
• Geoffrey Schick - Director, Strategic Site Partnerships - WCG
• Tina Bowdish - Senior Director, Clinical Research Administration - Vanderbilt-Ingram Cancer Center
• Lisa Switzer - CEO/Executive Director - Western States Cancer Research NCORP
• Rochelle Redding - Associate Director, Global Process Lead - Merck
4.The speaker communicated their content effectively.
Strongly disagree
Disagree
Agree
Strongly agree
• Geoffrey Schick - Director, Strategic Site Partnerships - WCG
• Tina Bowdish - Senior Director, Clinical Research Administration - Vanderbilt-Ingram Cancer Center
• Lisa Switzer - CEO/Executive Director - Western States Cancer Research NCORP
• Rochelle Redding - Associate Director, Global Process Lead - Merck
5.How can the organizers and speakers improve this session in the future?